NIGERIA – Àrgentil Capital Management Limited, a boutique investment banking firm, has announced its equity investment in Sygen Pharmaceuticals Limited that was structured via the sponsors’ investment vehicle, Consumer Growth Partners along with other co-investors.
Àrgentil invested in the transaction based on the management teams strong track record in excess of 155 years’ leading and managing operations of FMCG companies in Nigeria and other emerging markets.
APIP II’s investments have received award recognition including the Private Equity Africa 2019 Deal of the Year (Small Cap) award and many of our investee companies are making significant positive impact in the current COVID-19 environment.
Àrgentil also makes direct investments from its balance sheet to support management teams or sponsor new businesses that seek to create platforms that can scale over time to execute growth strategies in key sectors.
Sygen is an indigenous pharmaceutical company incorporated in 2019 to acquire the key operating assets of Nigerian German Chemicals (NGC). Prior to its acquisition NGC remained a well-known brand in Nigeria with operations spanning over 50 years.
Sygen produces and distributes pharmaceuticals products covering Analgesic, Anti-Diabetics, Antifungal, Anti-spasmodic, Cough medications and Hematinic drugs segments under the NGC brand name.
Sygen’s vision is to build a leading pharmaceutical business focused on manufacturing and distributing affordable quality drugs that are readily available and easily accessible to the middle and lower-income demographic of the economy.